AstraZeneca drops daily option in favor of weekly GLP-1 agonist

17 April 2023

As interest in GLP-1 agonists soars, AstraZeneca (LSE: AZN) has changed tack, stopping work on a daily injectable option in order to focus on an alternative which requires less regular jabs.

The British firm had been testing cotadutide in a Phase IIb/III study for the treatment of non-alcoholic steatohepatitis (NASH), among other indications.

Instead, the company will take forward AZD9550, another GLP-1/glucagon co-agonist, as part of its broader pipeline of NASH candidates.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK